{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:08:25Z","timestamp":1791223705100,"version":"4.1.0"},"reference-count":74,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,3,20]],"date-time":"2013-03-20T00:00:00Z","timestamp":1363737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>The administration of Bacillus Calmette\u2010Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high\u2010grade non\u2010muscle invasive bladder cancer (NMIBC) and carcinoma in\u2010situ (CIS) in terms of prevention of recurrence and progression. While most agree on a 6 week induction cycle, various maintenance schedules (if any at all) have been implemented without a unifying consensus.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This review assesses the historical emergence of BCG immunotherapy, beginning with its discovery as a vaccinatin for tuberculosis to its effect on the host immune system and potential therapeutic benefits for various oncologic conditions. The data establishing BCG immunotherapy as the standard of care for high\u2010grade NMIBC and CIS over other bladder instillation modalities is presented in addition to the effect maintenance BCG therapy has on sustaining the immuno\u2010protective effect.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                            acillus\n                            <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                            almette\u2010\n                            <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>\n                            u\u00e9rin (\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            ) immunotherapy is currently the most effective treatment of non\u2010muscle invasive bladder cancer and one of the most successful applications of immunotherapy to the treatment of cancer.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            This review summarises the history and development of\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            as a modern cancer treatment, appraises current optimal application of\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            immunotherapy in bladder cancer, discusses promising new therapies closely related to\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            , and briefly explores the possibility that\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            or related treatments may have an application in other urological malignancies.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            is a nonspecific stimulant to the reticuloendothelial system and induces a local inflammatory response with the infiltration of granulocytes followed by macrophages and lymphocytes, particularly helper T cells.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The initial\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            controlled trial showed a statistically significant reduction in tumour recurrence and found the advantage increased with duration of follow\u2010up. Similar results were reported in much higher risk patients in an independent concurrent study. Follow\u2010up suggested that a single 6\u2010week course of intravesical\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            provided long\u2010term protection (up to 10 years) from tumour recurrence and even reduced disease progression.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            While induction\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            (six weekly instillations) reduced recurrence, progression and mortality at 10 years, this advantage was lost by 15 years, and patients remained at high risk for progression without the use of maintenance\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            In a meta\u2010analysis by the Cochrane group, induction\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            was found to be markedly superior to mitomycin\n                            <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                            in high\u2010risk patients but not in low\u2010risk patients. Additionally, the\n                            <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>\n                            ational\n                            <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                            omprehensive\n                            <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                            ancer\n                            <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>\n                            etwork guidelines lists the use of intravesical\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            as preferred therapy, citing\n                            <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                            ategory 1 data for high\u2010grade\n                            <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\n                            a, all\n                            <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\n                            1, and any\n                            <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\n                            is tumours.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Maintenance\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            therapy may be the most important advance in\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            treatment of bladder cancer since the initial introduction. The risk of tumour recurrence and disease progression is life\u2010long in most patients, but the immune stimulation induced by\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            wanes with time.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Logarithmic dose reduction of\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            in patients with increasing side\u2010effects will typically prevent escalation of toxicity.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Simple dose reduction, appropriate antibiotics, and understanding treatment contraindications have greatly increased the safety of\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            . The 3\u2010week maintenance schedule for 3 years has been evaluated in randomised clinical trials and appears to be the current optimal treatment.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            With the success achieved in bladder cancer and the relative safety and economy of\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            , consideration should be given to further research for its effectiveness in other genitourinary malignancies.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11754.x","type":"journal-article","created":{"date-parts":[[2013,3,20]],"date-time":"2013-03-20T09:40:11Z","timestamp":1363772411000},"page":"288-297","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Bacillus\n                    <scp>C<\/scp>\n                    almette\u2010\n                    <scp>G<\/scp>\n                    u\u00e9rin immunotherapy for genitourinary cancer"],"prefix":"10.1111","volume":"112","author":[{"given":"Nilay M.","family":"Gandhi","sequence":"first","affiliation":[{"name":"James Buchanan Brady Urological Institute Johns Hopkins Medical Institutions  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Morales","sequence":"additional","affiliation":[{"name":"Queen's University  Kingston ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Lamm","sequence":"additional","affiliation":[{"name":"BCG Oncology University of Arizona  Phoenix AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/9780470170113.ch3","volume-title":"Cancer Vaccines and Tumor Immunity","author":"Lamm D","year":"2008"},{"key":"e_1_2_14_3_1","first-page":"35","volume-title":"EORTC Genitourinary Group Monograph 6: BCG in Superficial Bladder Cancer","author":"Crispen R","year":"1989"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0171-2985(11)80451-1"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-1339-5_7"},{"key":"e_1_2_14_6_1","first-page":"561","article-title":"Contribution a l'etude du bacilli tuberculuex bilie","volume":"9","author":"Calmette A","year":"1921","journal-title":"Ann Inst Pasteur"},{"key":"e_1_2_14_7_1","first-page":"35","volume-title":"BCG Vaccine: Tuberculosis\u2010Cancer","author":"Guerin C","year":"1980"},{"key":"e_1_2_14_8_1","first-page":"89","article-title":"Premunition des nouveau\u2010nes contre la tuberculose par le vaccine BCG (1921\u20131926)","volume":"2","author":"Calmette A","year":"1926","journal-title":"Ann Inst Pasteur"},{"key":"e_1_2_14_9_1","first-page":"1142","article-title":"Nouvelles recherch\u00e9 sur les causes des accidents de Lubeck","author":"Lange B","year":"1931","journal-title":"Rev Tuberc Extrait"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-189305000-00001"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007560709013"},{"key":"e_1_2_14_12_1","first-page":"97","article-title":"Cancer and tuberculosis","volume":"9","author":"Pearl R","year":"1929","journal-title":"Am J Hygeine"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1936.tb15958.x"},{"key":"e_1_2_14_14_1","first-page":"348","article-title":"Focal and general tissue responses to an avirulent tubercle bacillus (BCG) intracardiac route","volume":"22","author":"Rosenthal SR","year":"1936","journal-title":"Arch Path"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/184291a0"},{"key":"e_1_2_14_16_1","first-page":"295","volume-title":"BCG Vaccine: Tuberculosis\u2010Cancer","author":"Rosenthal SR","year":"1980"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-197410000-00029"},{"key":"e_1_2_14_18_1","first-page":"127","article-title":"Extracutaneous delayed hypersensitivity, particularly in the guinea\u2010pig bladder","volume":"10","author":"Coe JE","year":"1996","journal-title":"Immunology"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1974.03230440046032"},{"key":"e_1_2_14_20_1","first-page":"369","article-title":"Bacillus Calmette\u2010Guerin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors","volume":"14","author":"Lamm DL","year":"1977","journal-title":"Invest Urol"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.122"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"e_1_2_14_23_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette\u2010Guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm DL","year":"1974","journal-title":"J Urol"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-2033-3_17"},{"key":"e_1_2_14_25_1","first-page":"47","article-title":"Intravesical administration of bacillus Calmette\u2010Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial","volume":"69","author":"Pinsky CM","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1099"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42445-1"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116202"},{"key":"e_1_2_14_29_1","first-page":"181","article-title":"BCG\u2010induced interleukin\u20106 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines","volume":"9","author":"Bevers RF","year":"1998","journal-title":"Eur Cytokine Netw"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)53283-8"},{"key":"e_1_2_14_31_1","first-page":"4286","article-title":"Murine bladder carcinoma cells present antigen to BCG\u2010specific CD4+ T\u2010cell","volume":"52","author":"Lattime EC","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39365-5"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37668-1"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35678-1"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb05560.x"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0374"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00199531"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110243251703"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000052376"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_14_41_1","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm DL","year":"1992","journal-title":"Urol Clin North Am"},{"key":"e_1_2_14_42_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0022-5347(17)43158-2","article-title":"Bacillus Calmette\u2010Guerin immunotherapy","volume":"138","author":"Lamm DL","year":"1987","journal-title":"J Urol"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)43125-9"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.3.441"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.03.051"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66333-1"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"e_1_2_14_48_1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0022-5347(17)49748-5","article-title":"Long term protection in bladder cancer following intralesional immunotherapy","volume":"132","author":"Reichert DF","year":"1984","journal-title":"J Urol"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64043-8"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.04.038"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.024"},{"key":"e_1_2_14_52_1","doi-asserted-by":"crossref","unstructured":"BrausiM OddensJ SylvesterRet\u2009al.Bacillus Calmette\u2010Guerin: one third dose versus full dose and one year versus three years of maintenance. Final results of EORTC GU Cancers Group randomized trial 30962innon muscle invasive bladder cancer. AUA.2012. abstract 1665. Available at:http:\/\/www.aua2012.org\/abstracts\/process.cfm?title=Bladder+Cancer:+Superficial&searchType=title. Accessed November 2012","DOI":"10.1016\/j.juro.2012.02.1523"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1086\/314064"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66427-9"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.04.104"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64936-X"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.46.2.93"},{"key":"e_1_2_14_58_1","volume-title":"Guidelines for the Management of Non\u2010Muscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2010 Update","author":"American Urological Association","year":"2010"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00041-F"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003231"},{"key":"e_1_2_14_61_1","volume-title":"Clinical Practice Guidelines in Oncology: Bladder Cancer Including Upper Tract Tumours and Urothelial Carcinoma of the Prostate. Version 1","author":"National Comprehensive Cancer Network","year":"2012"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70472-1"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)53713-1"},{"key":"e_1_2_14_64_1","first-page":"749","article-title":"Metastatic renal cell carcinoma regression after nephrectomy and BCG immunotherapy","volume":"6","author":"Dagnone AJ","year":"1999","journal-title":"Can J Urol"},{"key":"e_1_2_14_65_1","first-page":"13","article-title":"Rovbut' II. [The late results of the combined treatment of kidney cancer patients]","volume":"5","author":"Mavrichev AS","year":"1990","journal-title":"Urol Nefrol (Mosk)"},{"key":"e_1_2_14_66_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0094-0143(21)00487-0","article-title":"Immunotherapy for metastatic renal cell carcinoma","volume":"20","author":"Wirth MP","year":"1993","journal-title":"Urol Clin North Am"},{"key":"e_1_2_14_67_1","first-page":"157","article-title":"Immunotherapy of prostatic carcinoma with bacillus Calmette\u2010Guerin","volume":"59","author":"Merrin C","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_14_68_1","first-page":"351","article-title":"Prostate carcinoma: intratumor BCG immunotherapy","volume":"49","author":"Robinson MR","year":"1978","journal-title":"Natl Cancer Inst Monogr"},{"key":"e_1_2_14_69_1","first-page":"2691","article-title":"Immunotherapy by BCG against prostate adenocarcinomas in anatomical compartments","volume":"14","author":"Pollard M","year":"1994","journal-title":"Anticancer Res"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990020302"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00294019"},{"key":"e_1_2_14_72_1","first-page":"293","article-title":"BCG adjuvant immunotherapy in carcinoma of the prostate: an interim report","volume":"6","author":"Guinan PD","year":"1978","journal-title":"Allergol Immunopathol (Madr)"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198202000-00012"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20138"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.02.606"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11754.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11754.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:15:43Z","timestamp":1761754543000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11754.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,20]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11754.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11754.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,20]]},"assertion":[{"value":"2013-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}